Curated News
By: NewsRamp Editorial Staff
June 03, 2026
Oncotelic and Sapu Nano Expand Phase 1b Trial of Sapu003
TLDR
- Oncotelic's Sapu003 expansion and GCT appointment accelerate clinical timeline, potentially offering early mover advantage in mTOR-targeted cancer therapy.
- Sapu003 uses Deciparticle platform for IV everolimus delivery, aiming for predictable systemic exposure in Phase 1b dose-escalation study SP-03-B101.
- Advancing Sapu003 may provide new treatment options for patients with mTOR-sensitive solid tumors, addressing high-unmet-need cancers.
- Sapu003 is an injectable form of everolimus, designed to bypass oral administration issues using nanoparticle technology.
Impact - Why it Matters
This news matters because Sapu003, an intravenous formulation of everolimus, could offer a more predictable and effective treatment option for patients with advanced mTOR-sensitive solid tumors. The shift from an Australia-based to a multinational development strategy, including plans for European expansion, signals potential for broader patient access and faster regulatory approvals. For investors, the advancement of Oncotelic's pipeline, backed by its AI platform and strategic partnerships, highlights the company's commitment to addressing high-unmet-need cancers, potentially impacting future treatment landscapes.
Summary
Oncotelic Therapeutics (OTCQB: OTLC) and Sapu Nano have announced the expansion of their Phase 1b clinical development program for Sapu003 (Everolimus for Injection), with the appointment of Global Clinical Trials (GCT) as the lead contract research organization for international execution of Study SP-03-B101. This move follows recent regulatory approvals supporting study expansion and marks the transition of the Sapu003 program from an Australia-based clinical effort toward a broader multinational development strategy, including planned expansion into Europe.
SP-03-B101 is an open-label Phase 1b dose-escalation study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumor activity of Sapu003 in patients with advanced mTOR-sensitive solid tumors. GCT has already completed key regulatory submissions ahead of schedule and initiated clinical operations, site activation and study management activities. Sapu003 is an intravenous formulation of everolimus developed using Sapu Nano’s Deciparticle(TM) platform, which is designed to improve drug delivery and provide more predictable systemic exposure than oral administration while supporting future global registrational studies.
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates. In addition to its directly owned and developed drug pipeline, Oncotelic benefits from a robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications and holds 75 issued patents. The Company also leverages its proprietary AI-enabled PDAOAI platform, which supports research, biomarker discovery, and regulatory processes through advanced data analysis and knowledge integration. Beyond its internal programs, Oncotelic licenses and co-develops select drug candidates through strategic partnerships and joint ventures, currently owning a 45% interest in GMP Bio, a joint venture advancing a complementary pipeline of therapeutic candidates.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Oncotelic and Sapu Nano Expand Phase 1b Trial of Sapu003
